3 Abstract Antithrombin, a plasma glycoprotein serpin, requires conformational activation by heparin to induce an anticoagulant effect, which is mediated through accelerated factor Xa inhibition. Heparin, a highly charged polymer and an allosteric activator of the serpin, is associated with major adverse effects. To design better, but radically different activators of antithrombin from heparin, we utilized a pharmacophore-based approach. A tetrahydroisoquinoline-based scaffold was designed to mimic four critical anionic groups of the key trisaccharide DEF constituting the sequence-specific pentasaccharide DEFGH in heparin.
Introduction
Antithrombin, a member of the serpin (serine proteinase inhibitor) family of proteins, is a major regulator of several proteinases, especially thrombin, factor Xa, and factor IX, which play pivotal roles in the coagulation cascade. Yet, antithrombin alone is a rather poor inhibitor of all three proteinases under physiologic conditions. [1] [2] [3] A naturally occurring polymer called heparin accelerates this weak inhibition several thousand-fold, [2] [3] [4] which is the reason for heparin's clinical use as an anticoagulant.
Heparin is a linear polysaccharide of varying chain length and is composed of uronic acid and glucosamine residues that are variably sulfated and acetylated. 3, 5 Both these features introduce major structural complexity in heparin, which is known to be associated with multiple adverse effects including hemorrhage, thrombocytopenia, osteoporosis and variable patient response. 6 These side-effects are reduced by using homogeneous heparin preparations such as fondaparinux, which is a synthetic five-residue sequence based on the naturally occurring DEFGH # sequence (Fig. 1 ).
The DEFGH sequence binds antithrombin with high affinity and induces an allosteric conformational change in the serpin that allows the inhibitor to better recognize its target proteinases, especially factor Xa, resulting in acceleration of inactivation. 4 DEFGH binds antithrombin in the pentasaccharide-binding site (PBS), 7 while in addition to interacting with PBS, full-length UFH interacts with an adjacent region called the extended heparin-binding site (EHBS). 8, 9 Detailed structure-activity studies show that several anionic groups of DEFGH are critical for its high-affinity interaction with antithrombin ( Fig. 1 10 Numerous attempts have been made to design or discover new molecules that activate antithrombin, 3, 11 however each of these searches has relied on utilizing a saccharide scaffold as a mimic of heparin. Implicit in these designs was the assumption that a saccharide scaffold was critical to induce antithrombin activation. We questioned this assumption and undertook the challenge of designing non-saccharide activators of the serpin. Non-saccharide, organic mimics of heparin are likely to offer special advantages such as greater non-ionic binding energy in antithrombin recognition, 12 greater hydrophobicity for possible oral delivery, greater synthetic accessibility, and higher specificity of action in comparison to heparin's numerous activities. 13 However, designing non-saccharide, antithrombin activators is intrinsically challenging. Three major hurdles compound this challenge. One, antithrombin activation is a two-step, induced-fit process in which the activator is expected to recognize both the native state and the activated state such that key interactions could be 'turned on' for conformational transformation. 4, 10 Secondly, heparin mimics invariably have to possess several negative charges, which can induce recognition of many electropositive domains on protein surfaces. Finally, large organic scaffolds that can contain multiple sulfate and carboxylate groups capable of mimicking heparin, or pentasaccharide DEFGH (~20-25 Å long), are difficult to design.
In our first attempt on designing non-saccharide antithrombin activators, we designed sulfated flavan-3-ol molecules ( Fig. 1 ) based on a receptor-based approach involving computerized hydropathic interaction (HINT) analyses. 12, 14 The sulfated flavan-3-ol molecules were found to bind antithrombin with an affinity comparable to DEF and accelerated factor Xa inhibition approximately 8-10-fold. We have now utilized a pharmacophore-based approach of 6 mimicking trisaccharide DEF to design tetrahydroisoquinoline-based sulfated activator IAS 5 ( Fig. 1 ). Our studies suggest that IAS 5 activates antithrombin nearly 30-fold, an increase of nearly 2 to 3-fold higher than the first generation rationally designed agents. 12, 14 This work advances the concept of antithrombin activation through non-saccharide, organic molecules and pinpoints a direction for the design of more potent molecules.
Experimental Procedures
Proteins and Chemicals ⎯ Antithrombin and factor Xa (human forms) were purchased 16 after which sodium dibasic phosphate (10 equiv) in H 2 O (2 mL) was added to the reaction mixture.
Following 15 min of stirring, the reaction mixture was loaded onto a Sephadex G10 column (160 cm) and chromatographed using water as an eluent. Fractions were combined, concentrated under vacuum and lyophilized to obtain the sodium salt of the carboxylate as a white solid.
Capillary electrophoresis of both products using a fused silica capillary in 20 mM sodium phosphate buffer, pH 2.3, at 10 kV showed a single peak with greater than 95% purity (see Supplementary Information). 10 and k ACT is the second-order rate constant of factor Xa inhibition by antithrombin -organic activator complex.
Results and Discussion
Rational design of tetrahydroisoquinoline-based activator. Our first generation agents, the flavanoid-based activators, were designed on the basis of a receptor-based approach involving computerized docking and scoring. 14 In this work, we utilized a pharmacophore-based approach to design potential heparin mimics. Trisaccharide DEF, rather than pentasaccharide 9 DEFGH, was chosen as the saccharide scaffold to mimic because of the expectation that the smaller de novo organic design would be easier to synthesize. In addition, it is known that both DEF and DEFGH conformationally activate antithrombin fully and equally (~300-fold). 10 Structure-activity studies show that three sulfate groups, i.e., the 6-O-sulfate on residue D and 3-O-sulfate and 2-N-sulfate on residue F, and the 6-carboxylate group of residue E are critical for conformational activation of antithrombin, while the trisaccharide scaffold only serves to position these groups for optimal interaction. 11,17 Thus, the pharmacophore was extracted and the four critical groups were connected in three-dimensional space using a linear carbon linker to arrive at a first 'blueprint' of an activator (Fig. 2) . The blueprint was transformed into a potential organic activator by introducing rigidity and simplifying the structure for rapid synthesis. In this process, several scaffolds were modeled and their 3D similarity with the pharmacophore assessed. IAS 5 , the tetrahydroisoquinoline-based activator containing an acid functionality and five sulfate groups, was selected because it retained the three-dimensional configuration of the four critical groups (Fig. 3) . In addition, the 2-N-sulfate of residue D was also effectively mimicked by a sulfate group of the isoquinoline ring.
Calculation of the root mean square deviation between the five corresponding groups gave a value of 2.0 Å (range 1.1 to 2.7 Å), which reduced to 1.6 Å when only the groups of the pharmacophore were considered. In this design, it is suggested that the bicyclic ring mimics the D and E rings, the unicyclic ring mimics ring F, and the carboxylate groups match each other. To assess the importance of selected groups, we chose to study ester analogs, IES 5 and IES 4 , as well as an acid derivative with one less sulfate group, IAS 4 .
Synthesis of isoquinoline-based sulfated activators.
Nearly all small organic sulfates reported in the literature are mono-or di-sulfated molecules, typically prepared using sulfur trioxide complexes with amines in a highly polar solvent (DMF or DMA). [18] [19] [20] Yet, as the number of -OH groups increase on a small scaffold, sulfation becomes progressively difficult because of anion crowding. We recently developed a rapid and high-yielding microwave-based synthesis of polysulfated organic molecules using trimethylamine-or pyridine-sulfur trioxide complexes in the presence of excess amine in anhydrous acetonitrile at 100 -120 O C. 15 However, the microwave-assisted sulfation failed to yield any sulfated products when the substrate was the polyphenolic molecule containing an acid group. It is possible that the presence of naked carboxylic acid functionality under microwave conditions induces degradation of organic sulfates resulting in multiple products. To circumvent this problem, the carboxylic acid ester in IES 4 and IES 5 was hydrolyzed in excellent yields by simply stirring with KBuO-t / H 2 O (2:1) in anhydrous DMSO at RT. 16 It is worthwhile to mention that this hydrolysis fails miserably when standard saponification conditions (NaOH/water) are used.
Equilibrium Dissociation Constant of Antithrombin Interaction with Sulfated
Isoquinoline-based Activators. Previously we have used fluorescence spectroscopy for measuring the affinity of ligands for antithrombin. For saccharide ligands, e.g., DEFGH and DEF, the ~30% increase in intrinsic tryptophan fluorescence affords a convenient signal for the determination of the K D of the interaction, 4,10 while for our first generation agents, i.e., (+)-CS and others, we used an external probe, TNS, to determine binding affinity. 12, 14 In this study, we found that interaction of our designed organic ligands with antithrombin resulted in a decrease in intrinsic tryptophan fluorescence that reached a plateau at high ligand concentrations (Fig. 4 ). An equivalent limiting decrease of ~100% was obtained for IAS 5 previously described. 10 The concentration dependence of the observed rate constant of factor Xa inhibition for each activator is shown in Figure 5 . group modification appears to be not tolerated well. This highlights the fidelity of pharmacophore-based design approach used in the study.
In comparison to the first generation flavan-based activators, 12, 14, 21 the new molecules were found to be ~1.5-3-fold better at antithrombin activation suggesting reasonable improvement in design. This implies that appropriate modifications to the scaffold, e.g., extension of the linker between the tetrahydroisoquinoline and phenyl rings to more closely mimic pentasaccharide DEFGH, may yield a more potent activator. A key consideration in the future design would be interactions with antithrombin's pentasaccharide binding site residues, specifically Lys114, Lys125 and Arg129, which are possibly not engaged well with IAS 5 resulting in significantly less efficacy as compared to trisaccharide DEF.
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Conclusions and Significance
Antithrombin activation is a complex process in which the energy of heparin binding at an allosteric site is transferred to the proteinase recognition domain. Heparin, nature's highly efficient activator, is a design pinnacle and emulating it through a radically novel, as-yet- Connecting the groups using a carbon framework followed by engineering of rigidity that matches their orientation gave rise to a 'blueprint', which was transformed into a synthetically plausible target, IAS 5 . 
